Clinical Trial Update: Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer

View source ↗

Summary

Pfizer tested Aromasin (exemestane) as adjuvant therapy in postmenopausal women with invasive estrogen receptor-positive early breast cancer. The trial was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Status: TERMINATED | Results posted: 2012-10-31